Pelthos Therapeutics Inc. (PTHS)

Market Cap	70.50M +588.0%
Revenue (ttm)	16.80M
Net Income	-43.32M
EPS	-23.04
Shares Out	3.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,181
Open	21.46
Previous Close	21.00
Day's Range	21.01 - 22.35
52-Week Range	9.00 - 54.29
Beta	3.94
Analysts	Strong Buy
Price Target	55.00 (+161.78%)
Earnings Date	Mar 19, 2026

About PTHS

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 92
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PTHS
• Website: https://pelthos.com

Analyst Summary

According to 5 analysts, the average rating for PTHS stock is "Strong Buy." The 12-month stock price target is $55.0, which is an increase of 161.78% from the latest price.

Price Target

$55.0

(161.78% upside)

Analyst Consensus: Strong Buy